An open label, randomized, single-dose, two-sequence, two-period, crossover comparative bioavailability study to assess the pharmacokinetic and safety profile of Dofetilide intravenous solution compared to Tikosyn® (Dofetilide) oral capsule in healthy subjects under fasting conditions.

2023-510176-31-00 Protocol D052019 Human pharmacology (Phase I) - Other Ended

Start 22 Jul 2024 · End 4 Nov 2024 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol D052019

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 20
Countries 1
Sites 2

This study is a phase I trial, a single-dose, open label, randomized, two-period, two-sequence, crossover bioavailability study comparing IV to oral Dofetilide.

Key facts

Sponsor
Hyloris Developments
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
22 Jul 2024 → 4 Nov 2024
Decision date (initial)
2024-07-03
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

This study is a phase I trial, a single-dose, open label, randomized, two-period, two-sequence, crossover bioavailability study comparing IV to oral Dofetilide.

VersionLevelCodeTermSystem organ class
20.0 LLT 10003663 Atrial flutter/ fibrillation 10007541

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Hyloris Developments

Sponsor organisation
Hyloris Developments
Address
Boulev. De Patience Et Beajonc 3 Bus 1
City
Liege
Postcode
4000
Country
Belgium

Scientific contact point

Organisation
Hyloris Developments
Contact name
Christophe Lyssens

Public contact point

Organisation
Hyloris Developments
Contact name
Christophe Lyssens

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 20 2
Rest of world 0

Investigational sites

Bulgaria

2 sites · Ended
Medical Center Comac Medical Ltd.
Clinical Research unit, Ulitsa Sveti Georgi Sofiyski 3, 1606, Sofia
Medical Center Comac Medical Ltd.
Clinical Research unit, Ulitsa Urvich 13, Krasno Selo District, Sofia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2024-07-22 2024-11-04 2024-07-23 2024-10-09

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-22 Bulgaria Acceptable
2024-07-03
2024-07-03
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-10-02 Bulgaria Acceptable
2024-07-03
2024-10-02
3 SUBSTANTIAL MODIFICATION SM-1 2024-10-03 Bulgaria Acceptable 2024-10-28
4 NON SUBSTANTIAL MODIFICATION NSM-2 2024-11-01 Bulgaria Acceptable 2024-11-01